BIOMARIN PHARMACEUTICAL INC

BioMarin Pharmaceutical Inc. completed its acquisition of Amicus Therapeutics, Inc. on April 27, 2026, for an aggregate transaction value of approximately $5,323.6 million. The acquisition was funded through $3,650.0 million in new borrowings and $1,836.0 million in cash on hand. This amendment provides the audited financial statements of Amicus and unaudited pro forma condensed combined financial information for the combined entity.

BioMarin Pharmaceutical Inc. held its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the 2017 Equity Incentive Plan, increasing the number of shares reserved for issuance by 7,650,000. Additionally, stockholders elected ten directors to the Board, ratified KPMG LLP as the independent auditor for the fiscal year ending December 31, 2026, and approved the compensation of named executive officers on an advisory basis. All proposals presented at the meeting received stockholder approval.

BioMarin Pharmaceutical Inc. reported a significant decrease in net income and diluted EPS for the first quarter of 2026, despite a modest increase in total revenues. Net income fell 43.17% to $105.5 million, with diluted EPS at $0.54. Total revenues grew 2.82% to $766.2 million, driven by a 3.46% rise in net product revenues. The company also issued $850.0 million in senior unsecured notes in February 2026, with proceeds earmarked for the Amicus acquisition, which closed in April 2026.

BioMarin Pharmaceutical Inc. reported first-quarter 2026 financial results, with total revenues increasing 3% year-over-year to $766 million. Despite a 43% decrease in GAAP Net Income to $106 million ($0.54 Diluted EPS) due to acquisition-related costs and a manufacturing charge, the company raised its full-year 2026 Total Revenues guidance to between $3.825 billion and $3.925 billion, reflecting accelerated growth from the recently completed Amicus Therapeutics acquisition. The acquisition adds GALAFOLD and POMBILITI + OPFOLDA to BioMarin's portfolio, though it is expected to be slightly dilutive to full-year Non-GAAP Diluted EPS, which was updated to $4.85 - $5.05.

BioMarin Pharmaceutical Inc. completed its acquisition of Amicus Therapeutics for approximately $4.8 billion in an all-cash transaction at $14.50 per share. This strategic move strengthens BioMarin's commercial portfolio by adding Galafold® for Fabry disease and Pombiliti® + Opfolda® for Pompe disease, along with U.S. rights to DMX-200. The company also entered into a new credit agreement and expects to provide updated FY 2026 guidance during its first quarter earnings call on May 4, 2026.

BioMarin Pharmaceutical Inc. announced that its merger with Amicus Therapeutics, Inc. has received clearance under French foreign direct investment screening procedures. This French FDI Clearance satisfies the final pre-closing condition for the merger, paving the way for the transaction. The acquisition is now expected to close on April 27, 2026, at which point Amicus will become a wholly owned subsidiary of BioMarin.